---
title: "Sunac China requests to postpone the hearing to January 5, 2026"
description: "According to the Zhitong Finance APP, Sunac China announced that on August 20, 2025, the High Court has canceled the petition hearing originally scheduled for August 25, 2025, and postponed the petiti"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253792772.md"
published_at: "2025-08-20T10:39:02.000Z"
---

# Sunac China requests to postpone the hearing to January 5, 2026

> According to the Zhitong Finance APP, Sunac China announced that on August 20, 2025, the High Court has canceled the petition hearing originally scheduled for August 25, 2025, and postponed the petition hearing to January 5, 2026

According to the Zhitong Finance APP, Sunac China (01918) announced that on August 20, 2025, the High Court has canceled the petition hearing originally scheduled for August 25, 2025, and postponed the petition hearing to January 5, 2026

### Related Stocks

- [01918.HK - Sunac China](https://longbridge.com/en/quote/01918.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| Amazon, Google And Others Are Pouring $700 Billion Into AI CapEx, Top Analyst Explains Why This Makes It 'Hard' To Bet Against Nvidia | Amazon, Microsoft, Meta, Tesla, Apple, and Google are set to invest nearly $700 billion in AI-driven capital expenditure | [Link](https://longbridge.com/en/news/275700100.md) |
| Prediction: This AI Stock Will Soar After Feb. 25. Here's Why. | Nvidia (NVDA) shares have faced a 2% decline over the past three months due to geopolitical tensions and concerns about  | [Link](https://longbridge.com/en/news/275701772.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.